In the Phase 2 obesity trial, which followed adults with obesity or overweight for 48 weeks, the average reductions in body weight were striking: To put that in perspective, at the 12 mg dose, more than eight in ten participants lost at least 15% of their starting body weight
People seeking a GLP-1 through Teladoc Health will see a provider with experience in obesity medicine
Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease
Please remember to bring in your lab requisitions, any lab kits, and insurance card for your lab visit
Data statistics are shown in Figure 8E
The Science Behind It: Semaglutide works by mimicking the GLP-1 hormone, which regulates appetite and food intake